Pre-earnings options volume in Pliant Therapeutics (PLRX) is 2.2x normal with calls leading puts 29:1. Implied volatility suggests the market is anticipating a move near 29.4%, or 43c, after results are released. Median move over the past eight quarters is 2.6%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics downgraded at Stifel after bexotegrast study discontinued
- Pliant Therapeutics downgraded to Hold from Buy at Stifel
- Leerink downgrades Pliant Therapeutics after trial discontinuation
- Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink
- Pliant Therapeutics price target lowered to $17 from $40 at Piper Sandler